@KathMLee1 ALL stems from https://t.co/bn86tfIesz
Could we knock-out Fas in CAR-T/TIL/TCR T cells to enhance treatment efficacy (in solid tumors) - just as being tested with knock-out of PD-1? -->https://t.co/SdrUEqOrrl
RT @Abyntek: Advancing chimeric antigen receptor T cell therapy with #CRISPR/Cas9 👇🏼 https://t.co/y2VtRXGZ9s
RT @Abyntek: Advancing chimeric antigen receptor T cell therapy with #CRISPR/Cas9 👇🏼 https://t.co/y2VtRXGZ9s
Advancing chimeric antigen receptor T cell therapy with #CRISPR/Cas9 👇🏼 https://t.co/y2VtRXGZ9s
RT @WilliamGerber1: https://t.co/P52AhipNBT $CLLS PATENT
https://t.co/P52AhipNBT $CLLS PATENT
RT @MaverickNY: Have an enormous pile of scientific papers to catch up on over w/e while traveling back to London. Starting w/ this: https:…
RT @MaverickNY: Have an enormous pile of scientific papers to catch up on over w/e while traveling back to London. Starting w/ this: https:…
Have an enormous pile of scientific papers to catch up on over w/e while traveling back to London. Starting w/ this: https://t.co/Dotx3nHtgG
#CRISPR Cas9[Ren & Zhaoレビュー]ヒトT細胞遺伝子編集と臨床応用;送達法;オフターゲット検出法;臨床応用に十分なオフターゲット抑制法;遺伝子ノックイン技術としての評価 Protein Cell 0422 https://t.co/gDwv9wK6IZ https://t.co/hiIvOJC2NI